These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9793870)

  • 41. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness.
    Haas GL; Garratt LS; Sweeney JA
    J Psychiatr Res; 1998; 32(3-4):151-9. PubMed ID: 9793868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.
    Biagi E; Capuzzi E; Colmegna F; Mascarini A; Brambilla G; Ornaghi A; Santambrogio J; Clerici M
    Adv Ther; 2017 May; 34(5):1036-1048. PubMed ID: 28382557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antipsychotic medication adherence in schizophrenia.
    Byerly MJ; Nakonezny PA; Lescouflair E
    Psychiatr Clin North Am; 2007 Sep; 30(3):437-52. PubMed ID: 17720031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The treatment of schizophrenia: Can we raise the standard of care?
    Catts SV; O'Toole BI
    Aust N Z J Psychiatry; 2016 Dec; 50(12):1128-1138. PubMed ID: 27821411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of clinical characteristics and antipsychotic medication prescribing practices of first-episode schizophrenia in Israel: a naturalistic prospective study.
    Strous RD; Bar F; Keret N; Lapidus R; Kosov N; Chelben J; Kotler M
    Isr J Psychiatry Relat Sci; 2006; 43(1):2-9. PubMed ID: 16910378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004.
    Gilmer TP; Dolder CR; Folsom DP; Mastin W; Jeste DV
    Psychiatr Serv; 2007 Jul; 58(7):1007-10. PubMed ID: 17602020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
    Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
    J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
    Stevens GL; Dawson G; Zummo J
    Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.
    Kane JM; Aguglia E; Altamura AC; Ayuso Gutierrez JL; Brunello N; Fleischhacker WW; Gaebel W; Gerlach J; Guelfi JD; Kissling W; Lapierre YD; Lindström E; Mendlewicz J; Racagni G; Carulla LS; Schooler NR
    Eur Neuropsychopharmacol; 1998 Feb; 8(1):55-66. PubMed ID: 9452941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
    Newcomer JW; Weiden PJ; Buchanan RW
    J Clin Psychiatry; 2013 Nov; 74(11):1108-20. PubMed ID: 24330898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Duration of untreated psychosis and the long-term course of schizophrenia.
    de Haan L; van Der Gaag M; Wolthaus J
    Eur Psychiatry; 2000 Jun; 15(4):264-7. PubMed ID: 10951611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quality of life and new antipsychotics in schizophrenia. Are patients better off?
    Awad AG; Voruganti LN
    Int J Soc Psychiatry; 1999; 45(4):268-75. PubMed ID: 10689610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antipsychotic combinations for schizophrenia.
    Ortiz-Orendain J; Castiello-de Obeso S; Colunga-Lozano LE; Hu Y; Maayan N; Adams CE
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009005. PubMed ID: 28658515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.